Medmira Stock Net Income

MMIRF Stock  USD 0.01  0  10.83%   
As of the 6th of February, MedMira secures the insignificant Risk Adjusted Performance, standard deviation of 16.42, and Mean Deviation of 4.13. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MedMira, as well as the relationship between them. Please verify MedMira mean deviation, total risk alpha, as well as the relationship between the Total Risk Alpha and kurtosis to decide if MedMira is priced some-what accurately, providing market reflects its recent price of 0.0133 per share. As MedMira appears to be a penny stock we also strongly suggest to check its information ratio numbers.
MedMira's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing MedMira's valuation are provided below:
MedMira does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Understanding that MedMira's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MedMira represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, MedMira's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.

MedMira 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to MedMira's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of MedMira.
0.00
11/08/2025
No Change 0.00  0.0 
In 3 months and 1 day
02/06/2026
0.00
If you would invest  0.00  in MedMira on November 8, 2025 and sell it all today you would earn a total of 0.00 from holding MedMira or generate 0.0% return on investment in MedMira over 90 days. MedMira is related to or competes with Cynata Therapeutics, Sernova Corp, Defence Therapeutics, Medical Developments, Novacyt SA, and Theralase Technologies. MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and tech... More

MedMira Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure MedMira's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess MedMira upside and downside potential and time the market with a certain degree of confidence.

MedMira Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for MedMira's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as MedMira's standard deviation. In reality, there are many statistical measures that can use MedMira historical prices to predict the future MedMira's volatility.
Hype
Prediction
LowEstimatedHigh
0.000.0116.96
Details
Intrinsic
Valuation
LowRealHigh
0.000.0116.96
Details
Naive
Forecast
LowNextHigh
0.00040.0216.97
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-0.00350.020.04
Details

MedMira February 6, 2026 Technical Indicators

MedMira Backtested Returns

MedMira has Sharpe Ratio of -0.015, which conveys that the firm had a -0.015 % return per unit of risk over the last 3 months. MedMira exposes nineteen different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify MedMira's Mean Deviation of 4.13, standard deviation of 16.42, and insignificant Risk Adjusted Performance to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 1.93, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, MedMira will likely underperform. At this point, MedMira has a negative expected return of -0.25%. Please make sure to verify MedMira's information ratio, as well as the relationship between the kurtosis and day typical price , to decide if MedMira performance from the past will be repeated at some point in the near future.

Auto-correlation

    
  0.69  

Good predictability

MedMira has good predictability. Overlapping area represents the amount of predictability between MedMira time series from 8th of November 2025 to 23rd of December 2025 and 23rd of December 2025 to 6th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of MedMira price movement. The serial correlation of 0.69 indicates that around 69.0% of current MedMira price fluctuation can be explain by its past prices.
Correlation Coefficient0.69
Spearman Rank Test0.26
Residual Average0.0
Price Variance0.0
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Based on the recorded statements, MedMira reported net income of (1.83 Million). This is 100.54% lower than that of the Health Care Equipment & Supplies sector and 102.61% lower than that of the Health Care industry. The net income for all United States stocks is 100.32% higher than that of the company.

MedMira Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MedMira's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of MedMira could also be used in its relative valuation, which is a method of valuing MedMira by comparing valuation metrics of similar companies.
MedMira is currently under evaluation in net income category among its peers.

MedMira Fundamentals

About MedMira Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze MedMira's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MedMira using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MedMira based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in MedMira Pink Sheet

MedMira financial ratios help investors to determine whether MedMira Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in MedMira with respect to the benefits of owning MedMira security.